BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Purpose: Despite initial sensitivity to chemotherapy, ovarian cancers (OVCA) often develop drug resistance, which limits patient survival. Using specimens and/or genomic data from 289 patients and a panel of cancer cell lines, we explored genome-wide expression changes that underlie the evolution of OVCA chemoresistance and characterized the BCL2 antagonist of cell death (BAD) apoptosis pathway as a determinant of chemosensitivity and patient survival. Experimental Design: Serial OVCA cell cisplatin treatments were performed in parallel with measurements of genome-wide expression changes. Pathway analysis was carried out on genes associated with increasing cisplatin resistance (EC50). BAD-pathway expression and BAD protein phosphorylation were evaluated in patient samples and cell lines as determinants of chemosensitivity and/or clinical outcome and as therapeutic targets. Results: Induced in vitro OVCA cisplatin resistance was associated with BAD-pathway expression (P < 0.001). In OVCA cell lines and primary specimens, BAD protein phosphorylation was associated with platinum resistance (n = 147, P < 0.0001) and also with overall patient survival (n = 134, P = 0.0007). Targeted modulation of BAD-phosphorylation levels influenced cisplatin sensitivity. A 47-gene BAD-pathway score was associated with in vitro phosphorylated BAD levels and with survival in 142 patients with advanced-stage (III/IV) serous OVCA. Integration of BAD-phosphorylation or BAD-pathway score with OVCA surgical cytoreductive status was significantly associated with overall survival by log-rank test (P = 0.004 and P < 0.0001, respectively). Conclusion: The BAD apoptosis pathway influences OVCA chemosensitivity and overall survival, likely via modulation of BAD phosphorylation. The pathway has clinical relevance as a biomarker of therapeutic response, patient survival, and as a promising therapeutic target. Clin Cancer Res; 17(19); 6356–66. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers
Jazaeri, A. A., Awtrey, C. S., Chandramouli, G. V. R., Chuang, Y. E., Khan, J., Sotiriou, C., Aprelikova, O., Yee, C. J., Zorn, K. K., Birrer, M. J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2682 · Cited by 192
Cited by
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
Pathway analysis of genomic data: concepts, methods, and prospects for future development
Ramanan, V. K., Shen, L., Moore, J. H., & Saykin, A. J. (2012) · Trends in Genetics · doi:10.1016/j.tig.2012.03.004 · Cited by 253
Bad phosphorylation as a target of inhibition in oncology
Bui, N.-L.-C., Pandey, V., Zhu, T., Ma, L., Basappa, & Lobie, P. E. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.017 · Cited by 86
Discovery of a small-molecule inhibitor of specific serine residue BAD phosphorylation
Pandey, V., Wang, B., Mohan, C. D., Raquib, A. R., Rangappa, S., Srinivasa, V., Fuchs, J. E., Girish, K. S., Zhu, T., Bender, A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1804897115 · Cited by 59
“Such examples would include ovarian cancer, in which BAD phosphorylation has been positively associated with dismal survival outcomes (10).”
BackgroundTargeting proapoptotic protein BAD inhibits survival and self-renewal of cancer stem cells
Sastry, K. S. R., Al-Muftah, M. A., Li, P., Al-Kowari, M. K., Wang, E., Ismail Chouchane, A., Kizhakayil, D., Kulik, G., Marincola, F. M., Haoudi, A., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.140 · Cited by 56
Metadata
- Authors
- Marchion, D. C., Cottrill, H. M., Xiong, Y., Chen, N., Bicaku, E., Fulp, W. J., Bansal, N., Chon, H. S., Stickles, X. B., Kamath, S. G., Hakam, A., Li, L., Su, D., Moreno, C., Judson, P. L., Berchuck, A., Wenham, R. M., Apte, S. M., Gonzalez-Bosquet, J., Bloom, G. C., Eschrich, S. A., Sebti, S., Chen, D.-T., & Lancaster, J. M.
- Venue
- Clinical Cancer Research
- Published
- 2011-10-01
- Volume
- 17
- Issue
- 19
- Pages
- 6356-6366
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W4241297146
- Cited by
- 100
- References
- 2
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-0735
- The paper
- Marchion, D. C., Cottrill, H. M., Xiong, Y., Chen, N., Bicaku, E., Fulp, W. J., Bansal, N., Chon, H. S., Stickles, X. B., Kamath, S. G., Hakam, A., Li, L., Su, D., Moreno, C., Judson, P. L., Berchuck, A., Wenham, R. M., Apte, S. M., Gonzalez-Bosquet, J., . . . Lancaster, J. M. (2011). BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-0735
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.